Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can targeted therapy combinations outperform standard drugs in tough thyroid cancer?

NCT ID NCT07770074

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study looks at how patients with radioiodine-refractory differentiated thyroid cancer are treated in the real world after first-line therapy stops working. It will compare two approaches: a targeted combination (dabrafenib plus trametinib) guided by a specific gene mutation, versus multi-targeted kinase inhibitors that work regardless of mutation status. By analyzing electronic health records of 200 Chinese adults, researchers hope to understand which patients receive which treatments and how long they stay on them. The goal is to inform better treatment decisions for this challenging condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dabrafenib plus trametinib (D+T) and multi-targeted tyrosine kinase inhibitors (MKIs) such as lenvatinib, sorafenib, anlotinib, and donafenib
What this could lead to
If successful, this research could help doctors choose the most effective second-line therapy for patients with this hard-to-treat thyroid cancer, potentially improving outcomes and quality of life.
What could go wrong
This is an observational study using existing medical records, so it cannot prove cause and effect. The results may be influenced by patient selection and data quality, and may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult RAI-R DTC patients from the rEHR database in China.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients with a diagnosis of thyroid cancer. * Patients with a pathological confirmation of differentiated thyroid cancer (DTC). * Patients who initiated either MKI monotherapy (lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib) or D+T combination therapy between January 1, 2019 and December 31, 2025 (or the data cutoff date). * Patients with no curative-intent thyroid cancer surgery within 3 months after initiation of systematic therapy. Exclusion criteria: • Patients participating in a blinded interventional clinical trial, or any open-label observational study involving D+T or MKI, during the study period. Other protocol-defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Radioiodine-refractory differentiated thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radioiodine-refractory differentiated thyroid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.